Literature DB >> 11241292

Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro.

T Kambayashi1, J Michaëlsson, L Fahlén, B J Chambers, C L Sentman, K Kärre, H G Ljunggren.   

Abstract

Natural killer cells have been shown to interact with MHC class I molecules via inhibitory receptors. However, it is not known whether the inhibition induced by MHC class I molecules requires other NK cell-target cell interactions. Thus, we examined whether purified MHC class I molecules alone were able to inhibit NK cell function. Purified H-2K(b) and H-2D(b) molecules inhibited the release of IFN-gamma from spleen (H-2(b))-derived lymphokine-activated killer (LAK) cell cultures stimulated by anti-NK1.1 antibody in a concentration-dependent manner. LAK cells generated from newborn mice that express low levels of MHC class I binding Ly49 inhibitory receptors were significantly less sensitive to inhibition by H-2K(b) compared to LAK cells from adult mice. Furthermore, LAK cells generated from spleen cells of Ly49C-transgenic mice were significantly more sensitive to inhibition by H-2K(b) compared to non-transgenic littermates. Taken together, the data indicate that MHC class I induced inhibition of NK cell mediated effector functions, as assessed by IFN-gamma release after NK1.1 triggering, does not require additional cell surface molecules other than MHC class I.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241292     DOI: 10.1002/1521-4141(200103)31:3<869::aid-immu869>3.0.co;2-a

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 2.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 3.  Assumptions of the tumor 'escape' hypothesis.

Authors:  Nicholas P Restifo; Paul A Antony; Steven E Finkelstein; Wolfgang W Leitner; Deborah P Surman; Marc R Theoret; Christopher E Touloukian
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

4.  Human NK cells differ more in their KIR2DL1-dependent thresholds for HLA-Cw6-mediated inhibition than in their maximal killing capacity.

Authors:  Catarina R Almeida; Amit Ashkenazi; Gitit Shahaf; Deborah Kaplan; Daniel M Davis; Ramit Mehr
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

Review 5.  Combinations of immunotherapy and radiation in cancer therapy.

Authors:  Ralph E Vatner; Benjamin T Cooper; Claire Vanpouille-Box; Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2014-11-28       Impact factor: 6.244

6.  Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.

Authors:  Andrea Castro; Kivilcim Ozturk; Rachel Marty Pyke; Su Xian; Maurizio Zanetti; Hannah Carter
Journal:  BMC Med Genomics       Date:  2019-07-25       Impact factor: 3.063

Review 7.  Paths taken towards NK cell-mediated immunotherapy of human cancer-a personal reflection.

Authors:  Hans-Gustaf Ljunggren
Journal:  Scand J Immunol       Date:  2020-11-20       Impact factor: 3.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.